Browse Articles

Discover research articles across all indexed journals

Author Correction: Neural–genetic–environmental evidence for a disease factor in mental and physical health multimorbidity

Nature Communications Jin Chen, Yuning Zhang, Shu Liu et al. Feb 05, 2026 DOI: 10.1038/s41467-026-69400-5

Frequency reproducibility of solid-state thorium-229 nuclear clocks

Nature Tian Ooi, Jack F. Doyle, Chuankun Zhang et al. Feb 05, 2026 DOI: 10.1038/s41586-025-09999-5

Transient protein structure guides surface diffusion pathways for electron transport in membrane supercomplexes

Nature Communications Chun Kit Chan, Jonathan Nguyen, Corey F. Hryc et al. Feb 05, 2026 DOI: 10.1038/s41467-025-67110-y

Integrative functional genomics analysis identifies pleiotropic genes for vascular diseases

Nature Communications Charles U. Solomon, David G. McVey, Catherine Andreadi et al. Feb 05, 2026 DOI: 10.1038/s41467-026-69273-8

Abstract Several vascular diseases including coronary artery disease, hypertension, stroke, and abdominal aortic aneurysm, have significant genetic underpinnings. Genome-wide association studies have unveiled many genetic loci associated with one or more of these diseases. However, the causative genes at most of these loci are yet to be determined, which hampers the translation of the genetic findings into a better understanding of the disease mechanisms and the identification of new therapeutic targets. Here, in an integrative functional genomics analysis of these loci, we identify a panel of likely causal genes, some of which are pleiotropic for more than one of these vascular diseases. Pooled CRISPR knockout screen analyses of these likely causal genes indicate that many of them influence vascular smooth muscle cell behaviour, and validation experiments of selected genes confirm that FES , BCAR1, CARF and SMARCA4 exert such effects. Further functional experiments focusing on FES , a pleiotropic gene for both coronary artery disease and hypertension, show that it modulates the expression of genes involved in vascular remodeling and that Fes knockout in mice promotes atherosclerosis as well as raises blood pressure. These findings provide an insight into the genetic basis of vascular diseases and inform targets for therapeutic development.

AI chatbots are infiltrating social-science surveys — and getting better at avoiding detection

Nature Sara Phillips Feb 05, 2026 DOI: 10.1038/d41586-026-00221-8

Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression

Nature Communications Vincent Cuminetti, Emeline Boet, Marcel Heugel et al. Feb 05, 2026 DOI: 10.1038/s41467-026-68906-2

Abstract Despite intriguing roles for the Succinate receptor (Sucnr1) in inflammation, few studies have explored its role in hematopoiesis. Here, we show that low SUCNR1 represents a marker for reduced overall and progression-free survival in acute myeloid leukemia (AML) patients. Succinic acid, which displays Sucnr1-dependent and independent effects, promotes disease in mouse models of pre-leukemic myelopoiesis, AML and AML xenografts, expressing low SUCNR1 . In vivo global or hematopoietic deletion of Sucnr1 induces expansion of hematopoietic stem and progenitor cells (HSPC) and hematopoiesis, whilst Sucnr1-tomato + HSPC display restricted engraftment potential. Mechanistically, activation of Sucnr1 counterbalances the stimulatory effect of intracellular succinate in HSPC and preserves HSPC transcriptional programs via control of S100a8/S100a9. Blocking S100a9 with tasquinimod rescues the defects of Sucnr1 knock-out mice, and combined with a potent Sucnr1 agonist shows therapeutic value in AML mice. In AML xenografts, single-cell RNA-sequencing reanalyses confirm SUCNR1 as a therapeutic vulnerability in patients. Together, Sucnr1 signaling restricts hematopoiesis at least partially through HSPC and via control of S100a8/S100a9. Its dysregulation emerges as contributor to malignancy that opens therapeutic avenues for AML patients.

Homo sapiens-specific evolution unveiled by ancient southern African genomes

Nature Mattias Jakobsson, Carolina Bernhardsson, James McKenna et al. Feb 05, 2026 DOI: 10.1038/s41586-025-09811-4

Abstract Homo sapiens evolved hundreds of thousands of years ago in Africa, later spreading across the globe 1 , but the early evolutionary process is debated 2–6 . Here we present whole-genome sequencing data for 28 ancient southern African individuals, including six individuals with 25× to 7.2× genome coverage, dated to between 10,200 and 150 calibrated years before present (cal.  bp) . All ancient southern Africans dated to more than 1,400 cal.  bp show a genetic make-up that is outside the range of genetic variation in modern-day humans (including southern African Khoe-San people, although some retain up to 80% ancient southern African ancestry), manifesting in a large fraction of Homo sapiens -specific variants that are unique to ancient southern Africans. Homo sapiens -specific variants at amino acid-altering sites fixed for all humans—which are likely to have evolved rapidly on the Homo sapiens branch—were enriched for genes associated with kidney function. Some Homo sapiens -specific variants fixed in ancient southern Africans—which are likely to have adapted rapidly on the southern African branch—were enriched for genes associated with protection against ultraviolet light. The ancient southern Africans show little spatiotemporal stratification for 9,000 years, consistent with a large, stable Holocene population transcending archaeological phases. While southern Africa served as a long-standing geographical refugium, there is outward gene flow over 8,000 years ago; however, inward gene flow manifests only after around 1,400 years ago. The ancient genomes reported here are therefore key to the evolution of Homo sapiens , and are important for advancing our understanding of human genomic variation.

Elective Cesarean Section for Maternal Preference

New England Journal of Medicine Abarna Pearl, Howard Minkoff, Gordon C.S. Smith Feb 05, 2026 DOI: 10.1056/nejmclde2504787

More on Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys

New England Journal of Medicine Feb 05, 2026 DOI: 10.1056/nejmc2517678

Exploring a New “Reef” in Dyslipidemic Risk Reduction

New England Journal of Medicine William E. Boden Feb 05, 2026 DOI: 10.1056/nejme2516860

Freedom of Speech and the Viability of Science — Dr. Jeremiah Stamler’s Fight against HUAC

New England Journal of Medicine Gerald M. Oppenheimer, Sarah W. Tracy Feb 05, 2026 DOI: 10.1056/nejmms2514344

Aortitis Due to Large-Vessel Vasculitis

New England Journal of Medicine Hsien-Tzung Liao, Ching-Lan Wu Feb 05, 2026 DOI: 10.1056/nejmicm2513456

Beta-Blockers after Myocardial Infarction — Toward Personalized Management

New England Journal of Medicine Thomas F. Lüscher, Florian A. Wenzl Feb 05, 2026 DOI: 10.1056/nejme2600427

A Matter of Time

New England Journal of Medicine Grant A. Wilson, Colin H. McLeish, Allan C. Gelber et al. Feb 05, 2026 DOI: 10.1056/nejmcps2508389

Health Insurance after Corporatization — What Next?

New England Journal of Medicine Leemore Dafny Feb 05, 2026 DOI: 10.1056/nejmp2415746

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

New England Journal of Medicine Sara M. Tolaney, Zefei Jiang, Qingyuan Zhang et al. Feb 05, 2026 DOI: 10.1056/nejmoa2508668

Sevabertinib in Advanced <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer

New England Journal of Medicine Feb 05, 2026 DOI: 10.1056/nejmc2517517

Still working at 107: supercentenarian study probes genetics of extreme longevity

Nature Mariana Lenharo Feb 05, 2026 DOI: 10.1038/d41586-026-00256-x

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

New England Journal of Medicine Neal D. Shore, Murilo de Almeida Luz, Ugo De Giorgi et al. Feb 05, 2026 DOI: 10.1056/nejmoa2510310

Floppy Eyelid Syndrome

New England Journal of Medicine Kara E. Shinder, Roman Shinder Feb 05, 2026 DOI: 10.1056/nejmicm2512228